Pharming PHAR
NASDAQ PHAR
$13.02 -0.14 (-1.06%)
As of: Nov 10, 2026 · 10:59 AM EST

Pharming (PHAR) Interest Expenses (2020 - 2021)

Updated

Analysis

Pharming (PHAR) Interest Expenses (2020 - 2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int Expense (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 217.00 Mn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 462.00 Mn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 435.00 Mn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 269.00 Mn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Pharming 898.85 Mn 429.52 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 -5.24 Mn
Mar 31, 2021 6.60 Mn
Dec 31, 2020 -12.99 Mn
API Access

Pharming Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=interest-expenses&ticker=PHAR&period=max&api_key=YOUR_API_KEY